DKN-01
Sponsors
Leap Therapeutics Inc., Leap Therapeutics, Inc., European Organisation for Research and Treatment of Cancer - EORTC, NYU Langone Health, Massachusetts General Hospital
Conditions
Adenocarcinoma of the Gastroesophageal JunctionBile Duct CancerBiliary Tract CancerCarcinoma of GallbladderCarcinoma of Intrahepatic and Extra-hepatic Biliary SystemCarcinosarcomaCholangiocarcinomaColo-rectal Cancer
Phase 1
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
CompletedNCT01457417
Start: 2012-01-31End: 2013-12-31Updated: 2016-09-28
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
CompletedNCT02375880
Start: 2015-06-30End: 2018-07-31Updated: 2025-08-03
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
TerminatedNCT03837353
Start: 2019-04-01End: 2022-09-20Updated: 2023-12-18
Phase 2
Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
WithdrawnNCT03818997
Start: 2019-12-31End: 2022-04-30Updated: 2020-02-05
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
TerminatedNCT04057365
Start: 2019-10-07End: 2022-09-25Updated: 2025-08-13
Phase 2 Study of DKN-01 in Colorectal Cancer
CompletedNCT05480306
Start: 2022-08-30End: 2025-07-10Updated: 2025-08-03
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
CompletedCTIS2022-501465-40-00
Start: 2023-12-22End: 2025-07-02Target: 25Updated: 2025-06-12
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Active, not recruitingNCT05761951
Start: 2023-08-29End: 2029-01-31Updated: 2026-02-11
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
CompletedCTIS2023-504940-32-00
Start: 2023-10-13End: 2025-02-17Target: 15Updated: 2024-09-26